Citation tools
"A phase 1/2 study to evaluate safety, biodistribution and anti-tumor activity of 177Lu-IPN01087 in patients with advanced or metastatic solid tumors expressing neurotensin receptor 1: trial in progress." Journal of Nuclear Medicine
60.supplement 1
(2019):
1281.
Web. 27 April. 2024.